FDA Approves Second CAR T-Cell Therapy for Lymphoma Patients
Published: May 1, 2018
Check out the video , on how CAR-T works . : )
It’s very informative and educational .
http://blog.dana-farber.org/insight/201 ... ocial_tool
FDA Approves Second CAR T-Cell Therapy for Lymphoma Patients Published: May 1, 2018
Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective
Abstract
This paper will summarize the data obtained primarily from the last decade of chimeric antigen receptor (CAR) T cell immunotherapy. It will do so in a manner that provides an overview needed to set the foundation for perspective on the state of research associated with CAR T cell therapy. The topics covered will include the construction of engineered CAR T cells from the standpoint of the different generations, the mode in which autologous T cells are transfected, the various biomarkers that have been used in CAR T cell immunotherapy, and setbacks associated with engineered T cells. Perspective on priorities of CAR T cell immunotherapy will also be addressed as they are related to safety and efficacy.
https://www.sciencedirect.com/science/a ... 7516300127
This paper will summarize the data obtained primarily from the last decade of chimeric antigen receptor (CAR) T cell immunotherapy. It will do so in a manner that provides an overview needed to set the foundation for perspective on the state of research associated with CAR T cell therapy. The topics covered will include the construction of engineered CAR T cells from the standpoint of the different generations, the mode in which autologous T cells are transfected, the various biomarkers that have been used in CAR T cell immunotherapy, and setbacks associated with engineered T cells. Perspective on priorities of CAR T cell immunotherapy will also be addressed as they are related to safety and efficacy.
https://www.sciencedirect.com/science/a ... 7516300127
Debbie
Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective
1. Introduction
Cancer therapy has evolved throughout the decades and is beginning to branch off into new and exciting fields including immunotherapy. The hope of this new field stems from the lack of success of chemotherapy in general. Chemotherapy's cytotoxic characteristics were regarded as one of three major methods of treating cancer. The other two methods include surgery and radiation. Due to a vast misunderstanding of the role of chemotherapy in late stage cancer, the likelihood of a full recovery from terminal cancer is close to zero [1]. Advances in genomics to aid in electing effective chemotherapeutic agents increased the success rate of cancer treatments, particularly when cancer has become metastatic [2]. Biomarkers are molecular characteristics of biological functions that can be readily measured or detected to determine cellular or physiological functions. Cancer biomarkers used in cancer research and treatment utilize this information to inform physicians and researchers of targets for chemotherapy in particular and can even be used to measure the effectiveness of treatments in some circumstances.
These genomics-based tests are predominantly centered on cancer biomarkers which have been used to further distinguish cancer cells and aid in the understanding of how the cells become cancerous. Some of these biomarkers are membrane bound proteins that serve various functions in cancer cells and even normal cells. However, these biomarkers from membrane-bound proteins are typically unique or over expressed. These kind of membrane-bound proteins that serve as cancer biomarkers can be carefully leveraged in immunotherapy. Membrane-bound antigenic proteins can be distinguished further as either being tumor associated antigen (TAA) and tumor specific antigens (TSA). TAAs are antigens that are over expressed in some cancers and can be found in other cells. TSA are antigens only found on cancers.
Cancer therapy has evolved throughout the decades and is beginning to branch off into new and exciting fields including immunotherapy. The hope of this new field stems from the lack of success of chemotherapy in general. Chemotherapy's cytotoxic characteristics were regarded as one of three major methods of treating cancer. The other two methods include surgery and radiation. Due to a vast misunderstanding of the role of chemotherapy in late stage cancer, the likelihood of a full recovery from terminal cancer is close to zero [1]. Advances in genomics to aid in electing effective chemotherapeutic agents increased the success rate of cancer treatments, particularly when cancer has become metastatic [2]. Biomarkers are molecular characteristics of biological functions that can be readily measured or detected to determine cellular or physiological functions. Cancer biomarkers used in cancer research and treatment utilize this information to inform physicians and researchers of targets for chemotherapy in particular and can even be used to measure the effectiveness of treatments in some circumstances.
These genomics-based tests are predominantly centered on cancer biomarkers which have been used to further distinguish cancer cells and aid in the understanding of how the cells become cancerous. Some of these biomarkers are membrane bound proteins that serve various functions in cancer cells and even normal cells. However, these biomarkers from membrane-bound proteins are typically unique or over expressed. These kind of membrane-bound proteins that serve as cancer biomarkers can be carefully leveraged in immunotherapy. Membrane-bound antigenic proteins can be distinguished further as either being tumor associated antigen (TAA) and tumor specific antigens (TSA). TAAs are antigens that are over expressed in some cancers and can be found in other cells. TSA are antigens only found on cancers.
Debbie